Apogee Therapeutics (APGE) Citi Annual Global Healthcare Conference 2025 summary

Key clinical milestones and data readouts

• 2026 will be a transformative year with multiple clinical readouts, including accelerated Q1 and Q2 data for lead program 777 in atopic dermatitis (AD) and asthma, plus a combo trial in the second half of the year.

• Part B Phase II will test dose response for 777 in AD, aiming to optimize dosing for Phase III.

• Maintenance data and head-to-head trials against DUPI are ongoing, with a focus on both efficacy and dosing frequency.

• Phase 1b asthma data in Q1 will target FeNO reduction, with a win defined as a 15–20 parts per billion decrease.

• Plans to start Phase II asthma trials later in the year, leveraging data from both AD and asthma studies.

Differentiation and product profile

• 777 offers every three- and six-month dosing, a significant advantage over current bi-weekly options, addressing needle fatigue and injection site pain.

• Rapid itch relief at 48 hours and strong EASI-75 results position 777 as a preferred product among physicians and patients.

• Market research shows high willingness to switch to 777 due to dosing convenience, with up to 90% of controlled patients preferring quarterly dosing.

• No injection site reactions observed in Part A; conjunctivitis rates are mild and not seen as a barrier by physicians.

• Product profile is already most preferred in AD, with further efficacy upside possible from higher dosing in Part B.

Market opportunity and commercial strategy

• Biologic penetration in AD is only 10%, offering significant growth potential; similar underpenetration exists in asthma and COPD.

• Market is growing rapidly, with new-to-brand prescriptions up 49% and overall market growth at 25% annually.

• 777 expected to be a first-line agent due to its efficacy, rapid relief, and dosing flexibility.

• Commercial access is strong for new entrants, with 80–90% coverage; payers favor products that offer patient choice and address unmet needs.

• Early engagement with payers and inclusion of auto-injector and prefilled syringe at launch are part of the access strategy.